Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).
After hours: March 19 at 4:05:13 PM EDT Loading Chart for GPK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback